

Torunn I Yock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/673967/publications.pdf>

Version: 2024-02-01

112
papers

5,055
citations

87888

38
h-index

95266

68
g-index

114
all docs

114
docs citations

114
times ranked

4135
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. <i>Lancet Oncology</i> , The, 2016, 17, 287-298.	10.7	263
2	Incidence of Second Malignancies Among Patients Treated With Proton Versus Photon Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 46-52.	0.8	241
3	An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. <i>Radiotherapy and Oncology</i> , 2012, 103, 8-11.	0.6	212
4	Proton Radiotherapy for Childhood Ependymoma: Initial Clinical Outcomes and Dose Comparisons. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 979-986.	0.8	191
5	Clinical Outcomes and Late Endocrine, Neurocognitive, and Visual Profiles of Proton Radiation for Pediatric Low-Grade Gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1060-1068.	0.8	166
6	Proton radiotherapy for orbital rhabdomyosarcoma: Clinical outcome and a dosimetric comparison with photons. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1161-1168.	0.8	153
7	Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. <i>Cancer</i> , 2014, 120, 126-133.	4.1	141
8	American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1057-1066.	0.8	140
9	Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091's Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3838-3843.	1.6	139
10	National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 152-168.	0.8	138
11	Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. <i>Neuro-Oncology</i> , 2013, 15, 1552-1559.	1.2	128
12	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2770-2777.	1.6	124
13	Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. <i>Neuro-Oncology</i> , 2016, 18, 881-887.	1.2	122
14	Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3762-3770.	1.6	117
15	Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 2854-2862.	1.6	111
16	Early Cognitive Outcomes Following Proton Radiation in Pediatric Patients With Brain and Central Nervous System Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 400-407.	0.8	110
17	Proton Radiotherapy for Pediatric Central Nervous System Germ Cell Tumors: Early Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 121-129.	0.8	109
18	Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 133-138.	0.8	105

#	ARTICLE	IF	CITATIONS
19	Prospective Study of Health-Related Quality of Life for Children With Brain Tumors Treated With Proton Radiotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 2079-2086.	1.6	101
20	Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 287-296.	0.8	101
21	A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. <i>Radiotherapy and Oncology</i> , 2014, 113, 77-83.	0.6	97
22	Proton Radiotherapy for Pediatric Bladder/Prostate Rhabdomyosarcoma: Clinical Outcomes and Dosimetry Compared to Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1367-1373.	0.8	94
23	Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. <i>Radiotherapy and Oncology</i> , 2014, 113, 89-94.	0.6	93
24	Technology Insight: proton beam radiotherapy for treatment in pediatric brain tumors. <i>Nature Clinical Practice Oncology</i> , 2004, 1, 97-103.	4.3	78
25	Patterns of Failure After Proton Therapy in Medulloblastoma; Linear Energy Transfer Distributions and Relative Biological Effectiveness Associations for Relapses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 655-663.	0.8	71
26	Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. <i>Radiotherapy and Oncology</i> , 2015, 116, 301-308.	0.6	68
27	Secondary Malignancy Risk Following Proton Radiation Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 261.	2.8	65
28	Radiation Therapy for Pediatric Central Nervous System Tumors. <i>Journal of Child Neurology</i> , 2009, 24, 1387-1396.	1.4	63
29	The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma. <i>Cancer</i> , 2019, 125, 290-297.	4.1	60
30	Cognitive and Adaptive Outcomes After Proton Radiation for Pediatric Patients With Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 391-398.	0.8	56
31	Brainstem Injury in Pediatric Patients With Posterior Fossa Tumors Treated With Proton Beam Therapy and Associated Dosimetric Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 719-729.	0.8	55
32	Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. <i>Cancer</i> , 2019, 125, 3242-3248.	4.1	55
33	Pediatric postoperative cerebellar cognitive affective syndrome follows outflow pathway lesions. <i>Neurology</i> , 2019, 93, e1561-e1571.	1.1	55
34	Proton therapy for paediatric CNS tumours "improving treatment-related outcomes. <i>Nature Reviews Neurology</i> , 2016, 12, 334-345.	10.1	50
35	Modern Radiotherapy for Pediatric Brain Tumors. <i>Cancers</i> , 2020, 12, 1533.	3.7	50
36	Proton Radiation Therapy for the Treatment of Retinoblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 863-869.	0.8	46

#	ARTICLE	IF	CITATIONS
37	Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. <i>Radiotherapy and Oncology</i> , 2018, 128, 44-55.	0.6	46
38	Bifocal intracranial tumors of nongerminomatous germ cell etiology: diagnostic and therapeutic implications. <i>Neuro-Oncology</i> , 2013, 15, 955-960.	1.2	44
39	Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. <i>Radiotherapy and Oncology</i> , 2019, 132, 155-161.	0.6	42
40	Left hippocampal dosimetry correlates with visual and verbal memory outcomes in survivors of pediatric brain tumors. <i>Cancer</i> , 2018, 124, 2238-2245.	4.1	41
41	An Update From the Pediatric Proton Consortium Registry. <i>Frontiers in Oncology</i> , 2018, 8, 165.	2.8	37
42	Evaluation of permanent alopecia in pediatric medulloblastoma patients treated with proton radiation. <i>Radiation Oncology</i> , 2014, 9, 220.	2.7	35
43	Executive functioning, academic skills, and quality of life in pediatric patients with brain tumors post-proton radiation therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 119-126.	2.9	35
44	Assessing the radiation-induced second cancer risk in proton therapy for pediatric brain tumors: the impact of employing a patient-specific aperture in pencil beam scanning. <i>Physics in Medicine and Biology</i> , 2016, 61, 12-22.	3.0	34
45	The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 860-874.	0.8	34
46	45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26540.	1.5	33
47	Risk of Second Cancers After Photon and Proton Radiotherapy. <i>Health Physics</i> , 2012, 103, 577-585.	0.5	32
48	Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2276-2283.	1.6	31
49	Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in Craniospinal Irradiation in Growing Pediatric Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 37-46.	0.8	29
50	A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 726-735.	0.8	29
51	Proton Therapy for Pediatric Ependymoma: Mature Results From a Bicentric Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 815-820.	0.8	27
52	Proton Radiation Therapy for Pediatric Craniopharyngioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1480-1487.	0.8	27
53	Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1152-1162.	1.5	26
54	Protons, the brainstem, and toxicity: Ingredients for an emerging dialectic. <i>Acta Oncologica</i> , 2014, 53, 1279-1282.	1.8	25

#	ARTICLE	IF	CITATIONS
55	Proton beam therapy in pediatric oncology. <i>Current Opinion in Pediatrics</i> , 2019, 31, 28-34.	2.0	25
56	An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology. <i>British Journal of Radiology</i> , 2020, 93, 20190673.	2.2	24
57	A Clarion Call for Large-Scale Collaborative Studies of Pediatric Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 980-981.	0.8	23
58	Long-term health-related quality of life in pediatric brain tumor survivors receiving proton radiotherapy at <lt;4 years of age. <i>Neuro-Oncology</i> , 2020, 22, 1379-1387.	1.2	22
59	Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3335-3339.	1.6	21
60	Brain tumors: Medulloblastoma, ATRT, ependymoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28395.	1.5	21
61	The role of proton therapy in pediatric malignancies: Recent advances and future directions. <i>Seminars in Oncology</i> , 2020, 47, 8-22.	2.2	20
62	Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 420-426.	0.8	18
63	Local Failure in Parameningeal Rhabdomyosarcoma Correlates With Poor Response to Induction Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 358-367.	0.8	18
64	Metabolic response as assessed by ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. <i>Cancer Medicine</i> , 2021, 10, 857-866.	2.8	18
65	Estimated IQ Systematically Underestimates Neurocognitive Sequelae in Irradiated Pediatric Brain Tumor Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 541-549.	0.8	17
66	Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology. <i>Medical Physics</i> , 2018, 45, e811-e819.	3.0	17
67	Quality of life in patients with proton-treated pediatric medulloblastoma: Results of a prospective assessment with 5-year follow-up. <i>Cancer</i> , 2018, 124, 3390-3400.	4.1	17
68	Cardiac and inflammatory biomarkers do not correlate with volume of heart or lung receiving radiation. <i>Radiation Oncology</i> , 2015, 10, 5.	2.7	16
69	The Pediatric Proton Consortium Registry: A Multi-institutional Collaboration in U.S. Proton Centers. <i>International Journal of Particle Therapy</i> , 2014, 1, 323-334.	1.8	16
70	Health-Related Quality of Life of Adolescent and Young Adult Survivors of Central Nervous System Tumors. <i>Journal of Pediatric Oncology Nursing</i> , 2015, 32, 385-393.	1.5	15
71	Elevation of Prostaglandin E ₂ in Lung Cancer Patients with Digital Clubbing. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1877-1878.	1.1	14
72	The Effect of Delaying Radiation Therapy for Systemic Chemotherapy on Local-regional Control in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 84, 161-171.	2.5	13

#	ARTICLE	IF	CITATIONS
73	Analysis of patient outcomes following proton radiation therapy for retinoblastoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 44-52.	1.2	12
74	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 67.	5.2	12
75	A comparison study assessing neuropsychological outcome of patients with post-operative pediatric cerebellar mutism syndrome and matched controls after proton radiation therapy. <i>Child's Nervous System</i> , 2020, 36, 305-313.	1.1	11
76	18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10549-10549.	1.6	9
77	Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 821-830.	0.8	8
78	Increased distance from a treating proton center is associated with diminished ability to follow patients enrolled on a multicenter radiation oncology registry. <i>Radiotherapy and Oncology</i> , 2019, 134, 25-29.	0.6	7
79	Prolongation of radiotherapy duration is associated with inferior overall survival in patients with pediatric medulloblastoma and central nervous system primitive neuroectodermal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28558.	1.5	7
80	Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy. <i>Neuro-Oncology</i> , 2021, 23, 156-166.	1.2	7
81	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 220-230.	0.8	7
82	Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy. <i>Neuro-Oncology</i> , 2022, 24, 1010-1019.	1.2	7
83	Proton beam therapy for medulloblastoma – Author's reply. <i>Lancet Oncology</i> , The, 2016, 17, e174-e175.	10.7	6
84	Assessing second cancer risk after primary cancer treatment with photon or proton radiotherapy. <i>Cancer</i> , 2020, 126, 3397-3399.	4.1	6
85	Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1044-1052.	0.8	6
86	Early results from Children's Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10015-10015.	1.6	6
87	Variation in Proton Craniospinal Irradiation Practice Patterns in the United States: A Pediatric Proton Consortium Registry (PPCR) Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 901-912.	0.8	6
88	Rethinking re consent when minors reach adult age in minimal risk studies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26731.	1.5	5
89	Factors Associated With Acute Toxicity in Pediatric Patients Treated With Proton Radiation Therapy: A Report From the Pediatric Proton Consortium Registry. <i>Practical Radiation Oncology</i> , 2022, 12, 155-162.	2.1	5
90	Radiation for pediatric low-grade gliomas: who will benefit and how late is soon enough?. <i>Neuro-Oncology</i> , 2020, 22, 1068-1069.	1.2	4

#	ARTICLE	IF	CITATIONS
91	Clinical outcomes of pediatric patients with autism spectrum disorder and other neurodevelopmental disorders and intracranial germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28935.	1.5	4
92	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 521-522.	27.6	3
93	Radiation Necrosis with Proton Therapy in a Patient with Aarskog-Scott Syndrome and Medulloblastoma. <i>International Journal of Particle Therapy</i> , 2022, 8, 58-65.	1.8	2
94	The role of proton beam therapy in central neurocytoma: A single-institution experience. <i>Practical Radiation Oncology</i> , 2018, 8, e305-e311.	2.1	1
95	Intra-arterial chemotherapy for rhabdomyosarcoma. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 391-396.	0.8	1
96	Patient Prioritization for Proton Beam Therapy in a Cost-neutral Payer Environment: Use of the Clinical Benefit Score for Resource Allocation. <i>Cureus</i> , 2019, 11, e5703.	0.5	1
97	Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience. <i>Neuro-Oncology</i> , 2022, 24, 2180-2189.	1.2	1
98	Posterior reversible encephalopathy syndrome and necrotizing enterocolitis in a pediatric patient with medulloblastoma and COVID-19 infection. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	1
99	RONC-20. VERTEBRAL BODY GROWTH RETARDATION FOLLOWING PROTON CRANIOSPINAL RADIATION. <i>Neuro-Oncology</i> , 2018, 20, i178-i178.	1.2	0
100	MBCL-47. OTOTOXICITY IN MEDULLOBLASTOMA SURVIVORS FOLLOWING PROTON RADIATION. <i>Neuro-Oncology</i> , 2018, 20, i127-i127.	1.2	0
101	NSRG-16. LESION LOCALIZATION IN POSTERIOR FOSSA SYNDROME. <i>Neuro-Oncology</i> , 2018, 20, i148-i149.	1.2	0
102	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i53-i53.	1.2	0
103	Multi-Institutional Data Collection and Analysis via the Pediatric Proton/Photon Consortium Registry. , 0, , .		0
104	Proton radiotherapy for rhabdomyosarcoma: Preliminary results from a multicenter prospective study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9585-9585.	1.6	0
105	Cost-effectiveness analysis of proton versus photon therapy with respect to risk of growth hormone deficiency.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17553-e17553.	1.6	0
106	Second non-ocular tumors among survivors of retinoblastoma treated with proton therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10018-10018.	1.6	0
107	HRQoL in medulloblastoma patients enrolled on a prospective phase II study of proton radiation.. <i>Journal of Clinical Oncology</i> , 2015, 33, e21029-e21029.	1.6	0
108	Systematic difference between Estimated IQ (EIQ) and Full Scale IQ (FSIQ) in survivors irradiated for pediatric brain tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10557-10557.	1.6	0

#	ARTICLE	IF	CITATIONS
109	RONC-24. PROTON THERAPY FOR PEDIATRIC EPENDYMOMA: MATURE OUTCOMES FROM THE UNIVERSITY OF FLORIDA AND MASSACHUSETTS GENERAL HOSPITAL. <i>Neuro-Oncology</i> , 2020, 22, iii460-iii460.	1.2	0
110	GCT-37. PREVALENCE OF AUTISM SPECTRUM DISORDER AND OTHER NEURODEVELOPMENTAL DISORDERS IN PEDIATRIC PATIENTS WITH INTRACRANIAL GERM CELL TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii335-iii335.	1.2	0
111	RADT-34. OLFACTORY PERCEPTION DURING PROTON RADIATION AND DIFFERENCES IN FREQUENCY OF OLFACTORY PERCEPTIONS BASED ON PROTON CRANIOSPINAL IRRADIATION TECHNIQUE FOR PEDIATRIC BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2021, 23, vi48-vi48.	1.2	0
112	RONC-14. Olfactory Perception During Proton Radiation and Differences in Frequency of Olfactory Perceptions Based on Proton Craniospinal Irradiation Technique for Pediatric Brain Tumor Patients.. <i>Neuro-Oncology</i> , 2022, 24, i179-i179.	1.2	0